These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9643710)

  • 41. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 42. Report slams US FDA's drug safety reform efforts.
    Bristol N
    Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
    [No Abstract]   [Full Text] [Related]  

  • 43. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
    Huh J; DeLorme DE; Reid LN; An S
    Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laetrile in historical perspective.
    Kardinal CG
    Mo Med; 1980 Sep; 77(9):564-9. PubMed ID: 7001210
    [No Abstract]   [Full Text] [Related]  

  • 45. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 46. Historical images of the drug market--LX. [Continued regularly].
    Helfand WH
    Pharm Hist; 1998; 40(4):147. PubMed ID: 11623626
    [No Abstract]   [Full Text] [Related]  

  • 47. Nutravigilance: principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry.
    Schmitz SM; Lopez HL; MacKay D
    Int J Food Sci Nutr; 2014 Mar; 65(2):129-34. PubMed ID: 24112316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Food and drug administration celebrates 75 years of consumer protection -- an album from the archives.
    Janssen WF
    Public Health Rep; 1981; 96(6):487-94. PubMed ID: 7029598
    [No Abstract]   [Full Text] [Related]  

  • 49. OpenVigil--free eyeballs on AERS pharmacovigilance data.
    Böhm R; Höcker J; Cascorbi I; Herdegen T
    Nat Biotechnol; 2012 Feb; 30(2):137-8. PubMed ID: 22318027
    [No Abstract]   [Full Text] [Related]  

  • 50. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 51. Monitoring for adverse drug events.
    Kennedy DL; Goldman SA
    Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003
    [No Abstract]   [Full Text] [Related]  

  • 52. [How do medicinal drugs work?-- On the varied history of the receptor concept (circa 1878 to circa 1970)].
    Prüll CR
    Praxis (Bern 1994); 2006 Jun; 95(25-26):1058-62. PubMed ID: 16836067
    [No Abstract]   [Full Text] [Related]  

  • 53. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The evolution of human medicines control from a national to an international perspective.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998 Mar; 17(1):19-50. PubMed ID: 9638280
    [No Abstract]   [Full Text] [Related]  

  • 55. Improving the reporting of adverse drug reactions in the hospital setting.
    Pushkin R; Frassetto L; Tsourounis C; Segal ES; Kim S
    Postgrad Med; 2010 Nov; 122(6):154-64. PubMed ID: 21084792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primer on medical device regulation. Part I. History and background.
    Monsein LH
    Radiology; 1997 Oct; 205(1):1-9. PubMed ID: 9314952
    [No Abstract]   [Full Text] [Related]  

  • 57. Adverse drug events and near misses: who's counting?
    Wu AW
    Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
    [No Abstract]   [Full Text] [Related]  

  • 58. WHO's international drug monitoring--the formative years, 1968-1975: preparatory, pilot and early operational phases.
    Venulet J; Helling-Borda M
    Drug Saf; 2010 Jul; 33(7):e1-e23. PubMed ID: 20553053
    [No Abstract]   [Full Text] [Related]  

  • 59. Why America needs a strong FDA.
    Markel H
    JAMA; 2005 Nov; 294(19):2489-91. PubMed ID: 16287960
    [No Abstract]   [Full Text] [Related]  

  • 60. The cancer "cures": a challenge to rational therapeutics.
    Janssen WF
    Anal Chem; 1978 Feb; 50(2):197A-202A. PubMed ID: 341747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.